Madrigal Pharmaceuticals Inc
MDGL
Company Profile
Business description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Contact
200 Barr Harbor Drive
Suite 200, Four Tower Bridge
West ConshohockenPA19428
USAT: +1 267 824-2827
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
528
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,820.30 | 6.40 | -0.07% |
| CAC 40 | 7,830.33 | 71.92 | -0.91% |
| DAX 40 | 24,230.82 | 225.99 | -0.92% |
| Dow JONES (US) | 44,650.64 | 192.34 | 0.43% |
| FTSE 100 | 8,928.71 | 46.95 | -0.52% |
| HKSE | 24,139.57 | 111.20 | 0.46% |
| NASDAQ | 20,630.66 | 19.33 | 0.09% |
| Nikkei 225 | 39,569.68 | 76.68 | -0.19% |
| NZX 50 Index | 12,686.68 | 73.52 | -0.58% |
| S&P 500 | 6,280.46 | 17.20 | 0.27% |
| S&P/ASX 200 | 8,580.10 | 9.10 | -0.11% |
| SSE Composite Index | 3,510.18 | 0.50 | 0.01% |